EyePoint Pharmaceuticals (EYPT) Tops Q1 EPS by 11c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q1 EPS of ($0.56), $0.11 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $7.39 million versus the consensus estimate of $7.91 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Snail, Inc. sets 1-for-5 reverse stock split to meet Nasdaq rules
• Honeywell Aerospace starts at Hold as aftermarket exposure tempers upside outlook